Brii Biosciences Limited (BRIBF)
OTCMKTS
· Delayed Price · Currency is USD
0.126
0.00 (0.00%)
At close: Jul 8, 2024
Brii Biosciences Revenue
Brii Biosciences had revenue of 22.16M CNY in the half year ending June 30, 2024, a decrease of -20.55%. This brings the company's revenue in the last twelve months to 38.38M, down -71.46% year-over-year. In the year 2023, Brii Biosciences had annual revenue of 56.32M, down -53.94%.
Revenue (ttm)
38.38M CNY
Revenue Growth
-71.46%
P/S Ratio
n/a
Revenue / Employee
299.84K CNY
Employees
128
Market Cap
96.03M USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 56.32M | -65.96M | -53.94% |
Dec 31, 2022 | 122.28M | 29.74M | 32.13% |
Dec 31, 2021 | 92.54M | 10.32M | 12.56% |
Dec 31, 2020 | 82.22M | 62.02M | 307.10% |
Dec 31, 2019 | 20.20M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sandoz Group AG | 10.11B |
Telix Pharmaceuticals Limited | 430.80M |
Elekta AB (publ) | 1.66B |
Ryman Healthcare Limited | 458.44M |
Verano Holdings Corp. | 897.57M |
Vireo Growth Inc. | 98.53M |
Medexus Pharmaceuticals Inc. | 104.76M |
Brii Biosciences News
- 5 weeks ago - Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA - PRNewsWire
- 7 months ago - Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024 - PRNewsWire
- 1 year ago - Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer - PRNewsWire
- 1 year ago - Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023 - PRNewsWire
- 1 year ago - Brii Biosciences Provides Latest Clinical Development and Corporate Updates - PRNewsWire
- 1 year ago - Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693 - PRNewsWire
- 1 year ago - Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders - PRNewsWire
- 1 year ago - Brii Bio Publishes 2022 Environmental, Social and Governance Report - PRNewsWire